United States
SureQuick HCV

Detection of Antibodies to Hepatitis C

The test is suitable for testing and screening in clinical and non-clinical settings using whole blood (from venipuncture or fingerstick), serum, or plasma specimens. Valuable diagnostic tool, this test extends to outreach programs and community health settings, enabling broader reach, beyond the conventional clinical landscape. CE marked as an in vitro diagnostic device.

Key Product Features:

• Simple procedure format1. Drop specimen sample
2. Add buffer
3. Wait for result
• Rapid results within 10 minutes
• Rapid detection of HCV antibodies in whole blood (both fingerstick and venipuncture), serum, or plasma.
• Ambient storage and transport conditions: 2°C - 30°C (36°F - 86°F).

Accurate & Reliable
• Over 100% accurate:◦ Sensitivity: 100%
◦ Specificity: 100%
• Includes a control line to confirm the validity of the test.
• Shelf life of 24 months from the date of manufacture
• Uses colloid gold conjugate and recombinant HCV proteins to selectively detect antibodies to HCV in hole blood, serum or plasma.

• Competitively priced for large-scale programs.
• Short lead times

Downloadable Information

Prevalence & Trends

Various clinical stages which can include periods of latent, asymptomatic infection, are characteristic of Hepatitis C (HCV). HCV is a preventable and curable viral infection transmitted through blood contact. If left untreated, it can lead to severe health complications, notably liver disease.

  • In 2019, WHO estimated 58 million people worldwide have hepatitis C, with 1.5 million new infections with chronic hepatitis C.(1)
  • In 2019, WHO estimated 290,000 people died from hepatitis C, primary liver cancer.(2)
  • Most people with chronic HCV infection are asymptomatic.(3)
  • In 2016, the WHO adopted a strategy to reduce new viral Hepatitis infections by 90% and reduce deaths by 65% by 2030.(4)
  1. CDC 2021, Global Viral Hepatitis: Millions of People are Affected
  2. WHO 2023, Hepatitis C,will%20develop%20chronic%20HCV%20infection
  3. (CDC 2022, Hepatitis C Questions and Answers for Health Professionals,including%20cirrhosis%20and%20liver%20cancer
  4. (4) WHO 2016, WHO encourages countries to act now to reduce deaths from viral hepatitis

Flexible Specimens for Clinical and Non-Clinical Settings

Step 1 -
Collect Specimen & transfer to the specimen area of the casette
Step 2 -
Add 2 drop of buffer and set timer
Step 3 -
Read between 10 and 20 minutes
Line in the C Zone

Line in the C & T Zones

Invalid Result
1. Line only in the T zone, or
2. Neither line shows


Training materials for our products are available and recommended to ensure proper utilization by healthcare professionals. These materials cover specimen handling, storage, and equipment maintenance, ensuring accurate results. Request more product information »

Product not available in all territories. Please contact us for details. Please read full instructions before use.

© OraSure Technologies Inc., 2024